Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease
Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients
Objective: Since zinc-chelating action of levodopa has been reported in the past, we measured serum zinc level in patients with Parkinson's disease (PD) at our…Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world
Objective: Advanced Parkinson’s disease manifests with “on-off” phenomenon, dyskinesias and increasing symptom severity . Managing it in developing countries is difficult given the low per…Impaired fonction of mirror neurons and the role of levodopa in PD patients
Objective: Study of the emotional mirroring and its modulation by levodopa treatment in fluctuating PD patients with no significant cognitive burden as assessed by regular…Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens
Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…Trends in first line therapy for PD in Wales: A 16 year observational study
Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…Pharmacokinetics of ABBV-951 Following 24-Hour Continuous Subcutaneous Infusion to Arm, Abdomen and Thigh
Objective: Characterize levodopa pharmacokinetics (PK) and safety/tolerability of ABBV-951 in healthy volunteers at 3 different subcutaneous (SC) infusion sites: Arm, Abdomen and Thigh Background: As…Advanced Stage of Parkinson’s Disease: From Identification to Characterization and Disease Burden Assessment Using a Nationwide Database
Objective: To identify and describe PD patients who were prescribed intensified therapy and compare their burden of disease with mild-moderate PD patients. Background: Real-world data…Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease
Objective: The study of the benefit of intestinal levodopa/carbidopa infusion(LCIG) in resistant ON-freezing of gait(FOG-ON) that appears after Subthalamic Nucleus Deep Brain Stimulation(NST-DBS) in Parkinson’s…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 57
- Next Page »